- Glaukos Announces First Quarter 2024 Financial Results
- Glaukos Announces the Release of its 2023 Sustainability Report
- Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
- Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
- Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
- Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 108.05 |
---|---|
High | 111.39 |
Low | 107.83 |
Bid | 105.50 |
Offer | -- |
Previous close | 107.62 |
Average volume | 516.48k |
---|---|
Shares outstanding | 50.37m |
Free float | 48.62m |
P/E (TTM) | -- |
Market cap | 5.56bn USD |
EPS (TTM) | -2.88 USD |
Data delayed at least 15 minutes, as of May 11 2024 00:00 BST.
More ▼